Fulgent Genetics (FLGT) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

FLGT Stock Forecast

Fulgent Genetics stock forecast is as follows: an average price target of $45.00 (represents a 169.30% upside from FLGT’s last price of $16.71) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

FLGT Price Target

The average price target for Fulgent Genetics (FLGT) is $45.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $50.00 to $40.00. This represents a potential 169.30% upside from FLGT's last price of $16.71.

FLGT Analyst Ratings

Buy

According to 2 Wall Street analysts, Fulgent Genetics's rating consensus is 'Buy'. The analyst rating breakdown for FLGT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Fulgent Genetics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Dec 08, 2022	-	Piper Sandler	$40.00	$37.07	7.90%	139.38%
Nov 18, 2022	-	Raymond James	$45.00	$35.89	25.38%	169.30%
Nov 14, 2022	-	Credit Suisse	$50.00	$39.24	27.42%	199.22%
May 15, 2022	David Westenberg	Piper Sandler	$70.00	$54.45	28.56%	318.91%

Row per page

Go to

The latest Fulgent Genetics stock forecast, released on Dec 08, 2022 by Piper Sandler company, set a price target of $40.00, which represents a 7.90% increase from the stock price at the time of the forecast ($37.07), and a 139.38% increase from FLGT last price ($16.71).

Fulgent Genetics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$16.71	$16.71	$16.71
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Fulgent Genetics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Fulgent Genetics's last price of $16.71. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Dec 08, 2022	Piper Sandler	Overweight	Neutral	Downgrade
Nov 18, 2022	Raymond James	-	Outperform	Initialise
Nov 14, 2022	Piper Sandler	Overweight	Overweight	Hold

Row per page

Go to

Fulgent Genetics's last stock rating was published by Piper Sandler on Dec 08, 2022. The company Downgrade its FLGT rating from "Overweight" to "Neutral".

Fulgent Genetics Financial Forecast

Fulgent Genetics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$84.69M	$67.85M	$66.17M	$67.70M	$105.66M	$125.34M	$320.27M	$251.67M	$227.87M	$153.62M	$359.43M	$294.98M	$101.72M	$17.27M	$7.75M	$8.39M	$10.35M
Avg Forecast	$96.45M	$93.66M	$91.01M	$83.66M	$85.80M	$83.49M	$80.82M	$73.89M	$74.86M	$71.72M	$69.07M	$65.36M	$66.32M	$64.42M	$62.48M	$60.05M	$59.57M	$91.36M	$122.70M	$270.85M	$191.10M	$264.00M	$197.34M	$321.51M	$199.46M	$48.46M	$10.02M	$7.74M	$8.51M	$8.44M
High Forecast	$99.06M	$96.20M	$93.48M	$85.92M	$88.13M	$85.75M	$83.01M	$75.37M	$77.25M	$71.72M	$69.07M	$65.36M	$66.37M	$64.42M	$64.18M	$61.68M	$61.18M	$91.36M	$122.70M	$270.85M	$191.10M	$264.00M	$197.34M	$321.51M	$199.46M	$48.46M	$10.02M	$7.74M	$8.51M	$8.44M
Low Forecast	$94.15M	$91.43M	$88.85M	$81.67M	$83.76M	$81.51M	$78.90M	$72.41M	$72.47M	$71.72M	$69.07M	$65.36M	$66.28M	$64.42M	$61.00M	$58.62M	$58.15M	$91.36M	$122.70M	$270.85M	$191.10M	$264.00M	$197.34M	$321.51M	$199.46M	$48.46M	$10.02M	$7.74M	$8.51M	$8.44M
# Analysts	1	1	1	1	1	1	1	2	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	10	16	8	11	7	11
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.31%	1.09%	1.10%	1.14%	1.16%	1.02%	1.18%	1.32%	0.86%	0.78%	1.12%	1.48%	2.10%	1.72%	1.00%	0.99%	1.23%

Fulgent Genetics's average Quarter revenue forecast for Dec 23 based on 2 analysts is $66.32M, with a low forecast of $66.28M, and a high forecast of $66.37M. FLGT's average Quarter revenue forecast represents a -21.69% decrease compared to the company's last Quarter revenue of $84.69M (Sep 23).

Fulgent Genetics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	10	16	8	11	7	11
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$214.00K	$-19.80M	$-22.86M	$-34.59M	$2.57M	$26.93M	$202.84M	$155.01M	$163.74M	$106.42M	$269.41M	$226.59M	$62.31M	$3.55M	$-1.11M	$473.00K	$2.03M
Avg Forecast	$31.20M	$30.30M	$29.45M	$27.07M	$27.76M	$27.01M	$26.15M	$23.91M	$24.22M	$23.20M	$22.35M	$21.15M	$21.46M	$20.84M	$20.22M	$19.43M	$19.27M	$27.69M	$37.19M	$141.67M	$57.93M	$80.02M	$59.82M	$239.07M	$60.46M	$14.69M	$3.04M	$-3.50M	$2.58M	$2.56M
High Forecast	$32.05M	$31.12M	$30.24M	$27.80M	$28.51M	$27.74M	$26.86M	$24.38M	$24.99M	$23.20M	$22.35M	$21.15M	$21.47M	$20.84M	$20.76M	$19.96M	$19.79M	$27.69M	$37.19M	$170.01M	$57.93M	$80.02M	$59.82M	$286.88M	$60.46M	$14.69M	$3.04M	$-2.80M	$2.58M	$2.56M
Low Forecast	$30.46M	$29.58M	$28.75M	$26.42M	$27.10M	$26.37M	$25.53M	$23.43M	$23.45M	$23.20M	$22.35M	$21.15M	$21.44M	$20.84M	$19.73M	$18.97M	$18.81M	$27.69M	$37.19M	$113.34M	$57.93M	$80.02M	$59.82M	$191.25M	$60.46M	$14.69M	$3.04M	$-4.20M	$2.58M	$2.56M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.01%	-0.98%	-1.18%	-1.79%	0.09%	0.72%	1.43%	2.68%	2.05%	1.78%	1.13%	3.75%	4.24%	1.17%	0.32%	0.18%	0.79%

2 analysts predict FLGT's average Quarter EBITDA for Dec 23 to be $21.46M, with a high of $21.47M and a low of $21.44M. This is 9926.90% upper than Fulgent Genetics's previous annual EBITDA (Sep 23) of $214.00K.

Fulgent Genetics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	10	16	8	11	7	11
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-13.11M	$-11.23M	$-15.85M	$-24.08M	$1.34M	$11.54M	$153.98M	$103.68M	$122.52M	$79.81M	$200.69M	$166.31M	$46.64M	$3.32M	$-1.96M	$-296.00K	$1.46M
Avg Forecast	$-2.42M	$2.07M	$1.57M	$-523.43K	$-3.08M	$632.32K	$122.09K	$-2.46M	$-3.73M	$-4.68M	$-9.09M	$127.43M	$-8.70M	$-9.73M	$-9.98M	$115.84M	$82.67M	$1.60M	$21.97M	$105.31M	$78.42M	$97.82M	$82.97M	$178.09M	$118.51M	$16.59M	$-1.27M	$-6.16M	$593.26K	$902.94K
High Forecast	$-2.34M	$2.14M	$1.62M	$-507.24K	$-2.98M	$654.59K	$126.39K	$-1.74M	$-1.77M	$-4.53M	$-8.80M	$152.91M	$-6.67M	$-9.43M	$-9.67M	$139.01M	$99.21M	$1.60M	$21.97M	$126.37M	$78.42M	$97.82M	$82.97M	$213.71M	$118.51M	$16.59M	$-1.27M	$-4.93M	$593.26K	$902.94K
Low Forecast	$-2.50M	$2.00M	$1.52M	$-541.86K	$-3.18M	$612.76K	$118.31K	$-3.18M	$-5.69M	$-4.84M	$-9.41M	$101.94M	$-10.73M	$-10.08M	$-10.33M	$92.67M	$66.14M	$1.60M	$21.97M	$84.25M	$78.42M	$97.82M	$82.97M	$142.47M	$118.51M	$16.59M	$-1.27M	$-7.39M	$593.26K	$902.94K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.35%	1.13%	-0.14%	-0.29%	0.84%	0.53%	1.46%	1.32%	1.25%	0.96%	1.13%	1.40%	2.81%	-2.61%	0.32%	-0.50%	1.62%

Fulgent Genetics's average Quarter net income forecast for Dec 22 is $82.67M, with a range of $66.14M to $99.21M. FLGT's average Quarter net income forecast represents a 6055.75% increase compared to the company's last Quarter net income of $1.34M (Sep 22).

Fulgent Genetics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	10	16	8	11	7	11
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$27.66M	$28.72M	$31.89M	$39.05M	$36.13M	$41.11M	$33.72M	$30.30M	$18.31M	$13.55M	$13.01M	$12.72M	$8.76M	$5.06M	$3.63M	$3.37M	$3.21M
Avg Forecast	$23.52M	$22.84M	$22.19M	$20.40M	$20.92M	$20.36M	$19.71M	$18.02M	$18.25M	$17.49M	$16.84M	$27.90M	$16.17M	$15.71M	$15.24M	$25.36M	$24.01M	$22.28M	$29.92M	$23.06M	$46.60M	$64.37M	$48.12M	$11.54M	$48.64M	$11.82M	$2.44M	$1.89M	$2.07M	$2.06M
High Forecast	$24.16M	$23.46M	$22.79M	$20.95M	$21.49M	$20.91M	$20.24M	$18.38M	$18.84M	$17.49M	$16.84M	$33.48M	$16.18M	$15.71M	$15.65M	$30.44M	$28.81M	$22.28M	$29.92M	$27.67M	$46.60M	$64.37M	$48.12M	$13.85M	$48.64M	$11.82M	$2.44M	$1.89M	$2.07M	$2.06M
Low Forecast	$22.96M	$22.29M	$21.67M	$19.91M	$20.42M	$19.87M	$19.24M	$17.66M	$17.67M	$17.49M	$16.84M	$22.32M	$16.16M	$15.71M	$14.87M	$20.29M	$19.21M	$22.28M	$29.92M	$18.45M	$46.60M	$64.37M	$48.12M	$9.24M	$48.64M	$11.82M	$2.44M	$1.89M	$2.07M	$2.06M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.76%	1.88%	1.26%	1.63%	1.62%	1.37%	1.46%	0.65%	0.28%	0.28%	1.13%	0.26%	0.74%	2.07%	1.92%	1.62%	1.56%

Fulgent Genetics's average Quarter SG&A projection for Dec 23 is $16.17M, based on 2 Wall Street analysts, with a range of $16.16M to $16.18M. The forecast indicates a -41.53% fall compared to FLGT last annual SG&A of $27.66M (Sep 23).

Fulgent Genetics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	10	16	8	11	7	11
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.44	$-0.38	$-0.54	$-0.81	$0.04	$0.38	$5.09	$3.46	$4.13	$2.74	$6.96	$6.55	$2.11	$0.15	$-0.09	$-0.01	$0.08
Avg Forecast	$-0.08	$0.07	$0.05	$-0.02	$-0.10	$0.02	-	$-0.08	$-0.12	$-0.15	$-0.30	$-0.32	$-0.29	$-0.32	$-0.33	$-0.43	$-0.56	$0.05	$0.73	$3.86	$2.61	$3.25	$2.76	$5.86	$3.94	$0.55	$-0.04	$0.02	$0.02	$0.03
High Forecast	$-0.08	$0.07	$0.05	$-0.02	$-0.10	$0.02	-	$-0.06	$-0.06	$-0.15	$-0.29	$-0.31	$-0.22	$-0.31	$-0.32	$-0.41	$-0.54	$0.05	$0.73	$3.86	$2.61	$3.25	$2.76	$5.86	$3.94	$0.55	$-0.04	$0.02	$0.02	$0.03
Low Forecast	$-0.08	$0.07	$0.05	$-0.02	$-0.10	$0.02	-	$-0.10	$-0.19	$-0.16	$-0.31	$-0.33	$-0.35	$-0.33	$-0.34	$-0.44	$-0.58	$0.05	$0.73	$3.86	$2.61	$3.25	$2.76	$5.86	$3.94	$0.55	$-0.04	$0.02	$0.02	$0.03
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.38%	1.16%	1.27%	1.45%	0.84%	0.52%	1.32%	1.33%	1.27%	0.99%	1.19%	1.66%	3.83%	-3.54%	-4.27%	-0.51%	2.67%

According to 1 Wall Street analysts, Fulgent Genetics's projected average Quarter EPS for Dec 22 is $-0.56, with a low estimate of $-0.58 and a high estimate of $-0.54. This represents a -1358.81% decrease compared to FLGT previous annual EPS of $0.04 (Sep 22).

Fulgent Genetics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
TTOO	T2 Biosystems	$0.51	$5.00	880.39%	Hold
FLGT	Fulgent Genetics	$16.71	$45.00	169.30%	Buy
GH	Guardant Health	$28.96	$57.27	97.76%	Buy
EXAS	Exact Sciences	$49.54	$89.67	81.01%	Buy
CRL	Charles River Laboratories	$187.50	$303.60	61.92%	Buy
ILMN	Illumina	$130.74	$202.44	54.84%	Buy
CDNA	CareDx	$21.56	$29.75	37.99%	Buy
DHR	Danaher	$230.06	$305.47	32.78%	Buy
TMO	Thermo Fisher Scientific	$501.29	$642.48	28.17%	Buy
A	Agilent	$126.92	$152.64	20.26%	Buy
MTD	Mettler-Toledo	$1.17K	$1.34K	14.46%	Hold
TWST	Twist Bioscience	$41.43	$42.40	2.34%	Buy
WAT	Waters	$355.47	$356.80	0.37%	Buy
NTRA	Natera	$153.42	$120.92	-21.18%	Buy

FLGT Forecast FAQ

Is Fulgent Genetics a good buy?

Yes, according to 2 Wall Street analysts, Fulgent Genetics (FLGT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of FLGT's total ratings.

What is FLGT's price target?

Fulgent Genetics (FLGT) average price target is $45 with a range of $40 to $50, implying a 169.30% from its last price of $16.71. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Fulgent Genetics stock go up soon?

According to Wall Street analysts' prediction for FLGT stock, the company can go up by 169.30% (from the last price of $16.71 to the average price target of $45), up by 199.22% based on the highest stock price target, and up by 139.38% based on the lowest stock price target.

Can Fulgent Genetics stock reach $30?

FLGT's average twelve months analyst stock price target of $45 supports the claim that Fulgent Genetics can reach $30 in the near future.

What are Fulgent Genetics's analysts' financial forecasts?

Fulgent Genetics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $324.01M (high $332.26M, low $316.57M), average EBITDA is $104.83M (high $107.5M, low $102.42M), average net income is $-4.783M (high $-3.938M, low $-5.639M), average SG&A $79.01M (high $81.02M, low $77.19M), and average EPS is $-0.157 (high $-0.129, low $-0.185). FLGT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $364.78M (high $374.66M, low $356.1M), average EBITDA is $118.02M (high $121.22M, low $115.21M), average net income is $695.89K (high $914.81K, low $479.95K), average SG&A $88.95M (high $91.36M, low $86.83M), and average EPS is $0.0229 (high $0.0301, low $0.0158).

Did the FLGT's actual financial results beat the analysts' financial forecasts?

Based on Fulgent Genetics's last annual report (Dec 2023), the company's revenue was $289.21M, beating the average analysts forecast of $253.28M by 14.19%. Apple's EBITDA was $-196M, missing the average prediction of $81.95M by -338.61%. The company's net income was $-168M, missing the average estimation of $87.43M by -291.96%. Apple's SG&A was $130.47M, beating the average forecast of $72.48M by 80.00%. Lastly, the company's EPS was $-5.63, beating the average prediction of $-1.361 by 313.74%. In terms of the last quarterly report (Sep 2023), Fulgent Genetics's revenue was $84.69M, beating the average analysts' forecast of $64.42M by 31.46%. The company's EBITDA was $214K, missing the average prediction of $20.84M by -98.97%. Fulgent Genetics's net income was $-13.107M, beating the average estimation of $-9.733M by 34.66%. The company's SG&A was $27.66M, beating the average forecast of $15.71M by 76.08%. Lastly, the company's EPS was $-0.44, beating the average prediction of $-0.32 by 37.50%